Punit Dhillon Email and Phone Number
Punit Dhillon work email
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
Punit Dhillon personal email
Experienced executive specializing in the life sciences industry, with a successful history of building and managing businesses, including publicly-traded companies. Adept at securing capital from healthcare institutions and overseeing product development for new medicine in areas such as vaccine development, cancer immunotherapy, ophthalmology and cardio-metabolic drugs. Over two decades of expertise encompass management, leadership development, corporate finance (M&A, capital raising, financial controls), operations, change management, governance, and business development (in/out-licensing, strategic partnerships with industry & academic institutions).Focused on guiding ventures from startup phase to IND enablement, CMC, and clinical proof-of-concept stages. Notable achievements include pre-clinical and clinical asset/product out-licensing deals with industry leaders such as Roche and Merck, along with drug development collaborations involving Wyeth (now Pfizer), BMS, Merck, and Genentech. Led turnaround of Skye Bioscience with completing several acquisitions and recent funding by specialist healthcare funds 5AM Ventures and Versant Ventures with two distinct, first- and only-in- class molecules for Phase 2 clinical trials.Established key channel partnerships, research collaborations, and IP in-licensing opportunities with respected academic institutions: UPENN, UCSF, USF, Ole Miss, University of Cordoba, and IMIBIC.
Skye Bioscience Inc.
View- Website:
- emeraldbio.life
- Employees:
- 18
-
Chief Executive Officer And DirectorSkye Bioscience Inc.San Diego, Ca, Us
-
Chief Executive Officer & DirectorSkye Bioscience Inc. Aug 2020 - PresentSan Diego, Ca, UsSkye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Skye’s is backed by 5AM Ventures, Versant Ventures, Perceptive Advisors, GSK Investments, Ally Bridge Group, Sphera Healthcare, Driehaus Capital and other successful specialist life science investors.Accomplishments: - Raised $150M+ in financing and deal value to support clinical development since joining as CEO, and established path to long-term value creation for shareholders.- Focused metabolic clinical development plan, (currently) Phase 2 stage.- Rebranded company to align with renewed focus.- Established from ground up, new BOD, scientific and clinical ad board, and management team.- Completed acquisition of Emerald Health Therapeutics, Inc. - Cumulative deal value ~$20M CAD.- Completed acquisition of Bird Rock Bio, Inc. - Cumulative deal value $20M USD.Chairman of Board of Directors - December 2019 - October 2024
-
Co-Founder & DirectorYell Canada Jun 2013 - PresentVancouver, British Columbia, CaThe Young Entrepreneur Leadership Launchpad (YELL) was founded by three Canadian entrepreneurs passionate about development program that could reach high school students across the country. A concept that would rest on the collective efforts of school district administrators, teachers, parents and business and community leaders. The program is a hands-on, experiential accelerator for high school students interested in gaining knowledge and development experience in all areas of business and entrepreneurship. YELL’s educational programs empower youth with the skills, knowledge and network they will need to take on the future. The YELL program is designed to feel like a university course to prepare students for the next phase in their educational journey, better-yet YELL is Canada’s first high school entrepreneurship program eligible for University credit.YELL exemplifies massive community engagement in action. Our combination of teachers, guest speakers, mentors, industry exploration activities and pitches give youth a network of support that can help them navigate their futures. We work with universities, companies, NPOs, school districts and governments to bring 21st Century skill-building academic experiences and opportunities to youth.YELL uses the principles of entrepreneurship to advance young leaders in any field. Through the integration of the United Nations SDGs, YELL is committed to developing global perspectives in youth and challenging them to tackle big ideas. We believe youth equipped with an entrepreneurial toolbox and a growth mindset will become creative problem solvers that will build a better future.For more information, please visit https://yellcanada.org. -
Managing DirectorTorpedo Publishing Llc May 2020 - PresentTorpedo Publishing was launched in 2020 as a multi-faceted publishing platform, serving to connect, inspire, and educate future game changers looking to positively impact the world. In late Spring 2021, we launched our first book under the Torpedo Publishing imprint. We are committed to building a complete, well-rounded multimedia brand with print, audio, and assorted digital elements. Our online Gift Shop features products curated to our readers’ tastes, made by brands we believe in.Torpedo Journal is a digital gazette on global affairs, sports, art, culture, design, and social impact. We believe that there is a globally-minded audience of readers who are hungry for opportunities, experiences, as well as inspiration from communities around the world. We strive to lend our platform to voices that seek this audience, elevating their stories for social change. As Torpedo Publishing continues to grow, at our core, we hold the simple belief that there will always be a place for a print and digital brand that is committed to telling fresh stories. We are humbled knowing that our success is the direct result of our relationship with our readers, advertisers, and collaborators who have supported us along the way. -
DirectorEmerald Health Sciences Inc. Feb 2017 - Aug 2020Emerald Health Sciences (EHS) is a private company that has strategic equity investments related to endocannabinoid based science and clinical products, including an early stage research pipeline with its wholly owned subsidiary, Vivacell Biotechnology Espana.- Responsible for private equity investments, overseeing the investment, operations and business development across several portfolio companies in North America and Europe. - Key management activities eventually spanned across seven different sites with a combined value of over $150 million.- Completed a Joint Venture that in the second year of business established itself as one of the best financial performers in Canada.- Launched comprehensive IP development strategy and negotiated several key in-licensing of patents with US and European academic institutions.- Involvement in the acquisition, founding, and funding of several innovative companies with a focus on capital-efficient models for drug R&D.- Led international regulatory engagement with several countries, advocating for evidence-based cannabis legalization policies, and ensuring global compliance.- Represented the Company in legislative and policymaking forums to shape responsible cannabis legalization frameworks.- Supervised the team that provided the support for strategic operations and evaluating new opportunities.- Maintained good relationships with investors, shareholders, partners, vendors, including liaising with buy-side and sell-side relationships, auditors, tax advisors and lawyers.- Post-Director role, as a principal shareholder, effectively led windup strategy for several business units with high success and transparency, delivering efficiency and cost savings.- Shareholder
-
Co-Founder (Former Ceo, Director)Oncosec Mar 2011 - Feb 2020San Diego, California, UsFounded OncoSec in March 2011, a San Diego-based biotechnology company, that I initially spin-out from Inovio Pharmaceuticals. We focused on pioneering new technologies to stimulate the body’s immune system to target and attack cancer based on intratumoral delivery of pIL-12. I led OncoSec through $250M in capital raised, listed on NASDAQ (in 2015) and launched the registration study KEYNOTE695 (in 2017) based on a drug collaboration with Merck. By November 2017, completed succession planning by recruiting and transitioning to new CEO with experience in late stage clinical development and commercialization. The primary product and clinical focus is the Phase 2 KEYNOTE695 study evaluating the effectiveness and safety of TAVO™, pIL12 plus electroporation in combination with pembrolizumab in patients with Stage III/IV melanoma. For more information, please visit: www.oncosec.com. Director: May 2018 - February 2020 (CoC to Sirtex/China Grand)President, and Director: November 2017 – May 2018 (CEO transition role)Co-Founder, President & CEO, Director: March 2011 – November 2017 (Exit) -
Vp, Finance & OperationsInovio Pharmaceuticals, Inc. Sep 2003 - Mar 2011Plymouth Meeting, Pa, UsRaised over $125 million through multiple financings and several licensing deals including early stage deals with Merck and Wyeth. Instrumental to the successful in-licensing of key intellectual property and a number of corporate transactions, including the acquisition and consolidation of Inovio AS, a Norwegian DNA delivery company, and the merger with VGX Pharmaceuticals, Inc. Lead consolidation post-merger and synergy assessment of over 30% in cost reduction and evaluation of non-core assets to advance DNA vaccine pipeline. Management experience spanned corporate finance, M&A, integration, successful in-licensing of key intellectual property, strategy implementation, corporate transactions and collaborations with leading Universities and working with several key opinion leaders across the globe. -
Law ClerkCatalyst Corporate Finance Lawyers Jan 1999 - Aug 2003
-
Intern AnalystMds Capital Corporation (Now Lumira Capital Corporation) Jul 1998 - Dec 2001Toronto, Ontario, Ca
Punit Dhillon Skills
Punit Dhillon Education Details
-
Simon Fraser UniversityPolitical Science & Business Administration -
Singularity UniversityExponential Technologies/Futuremed
-
Simon Fraser UniversityPolitical Science & Business
Frequently Asked Questions about Punit Dhillon
What company does Punit Dhillon work for?
Punit Dhillon works for Skye Bioscience Inc.
What is Punit Dhillon's role at the current company?
Punit Dhillon's current role is Chief Executive Officer and Director.
What is Punit Dhillon's email address?
Punit Dhillon's email address is pd****@****ld.life
What schools did Punit Dhillon attend?
Punit Dhillon attended Simon Fraser University, Singularity University, Simon Fraser University.
What are some of Punit Dhillon's interests?
Punit Dhillon has interest in Children, Education, Environment, Science And Technology, Human Rights, Arts And Culture, Health.
What skills is Punit Dhillon known for?
Punit Dhillon has skills like Vaccines, Outlook, Biotechnology, Clinical Development, Lifesciences, Pharmacology, Leadership, Technology Transfer, Biopharmaceuticals, Infectious Diseases, Immunology, Commercialization.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial